TOKYO (dpa-AFX) - Daiichi Sankyo Company Limited (DSKYF.PK)reported that its
profit attributable to owners of the company for the first nine months of fiscal
2016 decreased 20.4 percent to 88.18 billion yen from 110.73 billion yen in the
Kite Pharma has negotiated separate agreements with Fosun Pharma and with Daiichi Sankyo for the development of its lead CD19 chimeric antigen receptor (CAR) T-cell autologous cell therapy, axicabtagene ciloleucel (KTE-C19), in Japan and China,...
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article.
You may also be interested in articles related to Daiichi Sankyo Company (4568-TO):